REG - Theracryf PLC - Total Voting Rights

TheracryfAnnouncement

02/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240502:nRSB9121Ma&default-theme=true

RNS Number : 9121M  Theracryf PLC  02 May 2024

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Total Voting Rights

 

Alderley Park, UK - 2 May 2024:  In accordance with Disclosure Guidance and
Transparency Rule 5.6.1, the Company would like to notify the market that as
of 30 April 2024, the total number of Ordinary Shares in issue is 427,346,895,
with no shares held in treasury. This is the figure that may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

- Ends -

 

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

Dr Huw Jones, CEO
enquiries@theracryf.com

Toni Hänninen, CFO

 Dr Helen Kuhlman, CBO
 Cavendish Capital Markets (NOMAD and Broker)                +44 20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)
 Instinctif Partners                                         +44 207 457 2020

                                                           Theracryf@Instinctif.com
 Melanie Toyne-Sewell / Jack Kincade

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications such as neurodevelopmental disorders, glioblastoma*, addiction,
anxiety and narcolepsy* [*orphan indications]. Its strategy is to generate
compelling data sets to proof of concept and/or later phase II to partner its
clinical programmes with mid-size to large pharma. As well as a number of
industry partnerships with companies, including Stalicla, in neurodevelopment
disorders and has sourced programmes from companies such as Takeda and Shire,
the Company has worked with and has ongoing collaborations with major
universities, hospitals and government organisations such as the University of
Manchester, Sapienza (Università di Roma), Kings College London and
University of Connecticut.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is listed on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C%3A/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)
 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRQKDBQFBKDNPK